International Journal of Gynecological Cancer最新文献

{"title":"Revolutionizing first-line cervical cancer treatment: bevacizumab, immunotherapy, and emerging insights.","authors":"Wesley Antonio Lopes de Lima, Mariana Carvalho Gouveia, Louize Caroline Marques Oliveira, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.101661","DOIUrl":"10.1016/j.ijgc.2025.101661","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101661"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Providing tertiary gynecologic oncology care for Quebec's indigenous population in Montreal.","authors":"Gabriel Levin, Reitan Ribeiro, Lucy Gilbert, Shuk On Annie Leung, Joanne Power, Xing Zeng","doi":"10.1016/j.ijgc.2025.101900","DOIUrl":"10.1016/j.ijgc.2025.101900","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 6","pages":"101900"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of lymph node metastases in patients with apparent early-stage endometrioid ovarian carcinoma.","authors":"Dimitrios Nasioudis, Stefan Gysler, Nawar A Latif, Robert L Giuntoli, Sarah H Kim, Emily M Ko","doi":"10.1016/j.ijgc.2025.101897","DOIUrl":"10.1016/j.ijgc.2025.101897","url":null,"abstract":"<p><p>The incidence of lymph node metastases for apparent early-stage endometrioid ovarian carcinoma is not well-known. We accessed the National Cancer Database and selected patients with apparent stage I endometrioid ovarian carcinoma undergoing surgery between 2004 and 2015. The rate of lymphadenectomy was 76.9%, with a median of 12.5 lymph nodes removed. The overall incidence of lymph node metastasis was 2.2%, specifically, 1.2% for grade 1, 2.2% for grade 2, and 5.1% for grade 3 tumors (p < .001). After controlling for disease sub-stage, patients with grade 2 tumors were nearly twice (OR 1.78, 95% CI 1.20 to 2.63), and patients with grade 3 tumors were nearly 4 times (OR 4.1, 95% CI 2.74 to 6.22) as likely as those with grade 1 tumor to have lymph node metastases. Surgical staging identifies a very low rate of lymph node metastases for patients with apparent early-stage grade 1 endometrioid ovarian carcinoma, suggesting that lymphadenectomy can be omitted for these patients.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 6","pages":"101897"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-port robotic fertility-sparing surgery for clear cell ovarian carcinoma.","authors":"Filippo Maria Capomacchia, Benedetta Alberghetti, Giacomo Guidi, Francesco Fanfani, Giovanni Scambia, Anna Fagotti, Luigi Carlo Turco","doi":"10.1016/j.ijgc.2025.101899","DOIUrl":"10.1016/j.ijgc.2025.101899","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 6","pages":"101899"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radical parametrial resection with nerve-sparing approach: selective systematic nerve-sparing type C2 radical hysterectomy.","authors":"Ilker Selcuk, Stoyan Kostov, Hakan Rasit Yalcin","doi":"10.1136/ijgc-2024-006079","DOIUrl":"10.1136/ijgc-2024-006079","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101834"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on \"Effect of uterine manipulator on oncologic outcome in early-stage, low-grade endometrial cancer\" by Ye et al.","authors":"Fazil Avci","doi":"10.1016/j.ijgc.2025.101761","DOIUrl":"10.1016/j.ijgc.2025.101761","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101761"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of surgical complexity on disease-free survival and overall survival in newly diagnosed advanced ovarian cancer.","authors":"Víctor Lago, Blanca Novillo-Del Álamo, Marta Arnáez, Iria Rey, Pablo Padilla-Iserte, Luis Matute, Marta Gurrea, Santiago Domingo","doi":"10.1016/j.ijgc.2025.101821","DOIUrl":"10.1016/j.ijgc.2025.101821","url":null,"abstract":"<p><strong>Objective: </strong>Ovarian cancer surgery and the complexity of the procedure may be measured with the standardized Aletti score. The main objective of this study was to establish the influence of surgical complexity using the Aletti score on disease-free survival and overall survival.</p><p><strong>Methods: </strong>A retrospective observational study was conducted in a reference gynecologic oncology department, including advanced ovarian cancer patients, newly diagnosed who underwent a primary debulking surgery or interval debulking surgery between January 2010 and December 2019 (stage IIB-IV International Federation of Gynecology and Obstetrics classification), and epithelial histology. Incomplete medical records, loss to follow-up patients, and borderline histologies were excluded. Survival analysis and multivariate analysis were performed.</p><p><strong>Results: </strong>A total of 399 patients were included in the study. Regarding Aletti score complexity, no differences were observed in disease-free survival (median: 25 vs 24 months, p = .5) or overall survival (median: 56 vs 49 months, p = .6). Complete cytoreduction was associated with better disease-free survival (median: complete 26 vs optimal 14 vs sub-optimal 9 months, p < .0001) and overall survival (p < .0001). Furthermore, primary debulking surgery showed statistically better disease-free survival (median: 25 vs 16 months, p < .0001) and overall survival (median: 72 vs 38 months, p < .0001) compared to interval debulking surgery. The multivariable analysis showed that disease-free survival, overall survival, International Federation of Gynecology and Obstetrics classification, CA125 level at diagnosis, cytoreduction classification achieved after surgery, and the Clavien-Dindo complications did not significantly associate with the Aletti score.</p><p><strong>Conclusions: </strong>Disease-free survival and overall survival were not influenced by the surgical complexity in patients undergoing cytoreduction after the first diagnosis of advanced ovarian cancer. A higher Aletti score was not associated with a higher rate of complications.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 6","pages":"101821"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extending the timing for secondary cytoreductive surgery after second-line chemotherapy in relapsed ovarian cancer: the EXTENSION study.","authors":"Carmine Conte, Luigi Congedo, Claudia Marchetti, Francesca Romana Scanu, Giulia Parise, Valentina Ghirardi, Andrea Rosati, Giovanni Scambia, Anna Fagotti","doi":"10.1016/j.ijgc.2025.101824","DOIUrl":"10.1016/j.ijgc.2025.101824","url":null,"abstract":"<p><strong>Objective: </strong>Relapse remains a major issue for patients with advanced epithelial ovarian cancer. Based on the DESKTOP III trial, international guidelines recommend secondary cytoreduction surgery when feasible before starting chemotherapy in platinum-sensitive relapsed ovarian cancer. Currently, neoadjuvant chemotherapy before secondary cytoreduction surgery is not advised outside of clinical trials. Recently, CHIPOR trial has shown the efficacy of secondary cytoreduction surgery with hyperthermic intra-peritoneal chemotherapy after neoadjuvant chemotherapy in an unselected population with platinum-sensitive relapsed ovarian cancer. The primary aim of this study was to assess the rate of potential delayed secondary cytoreduction surgery after 6 cycles of neoadjuvant chemotherapy.</p><p><strong>Methods: </strong>This retrospective, monocentric, observational study included patients with platinum-sensitive relapsed ovarian cancer deemed unsuitable for secondary cytoreductive surgery after evaluation by a multidisciplinary tumor board and/or diagnostic laparoscopy from January 2020 to December 2023. After 6 cycles of neoadjuvant chemotherapy, secondary cytoreduction surgery feasibility was evaluated by applying criteria for upfront secondary cytoreduction surgery in patients with at least a partial response at computed tomography scan.</p><p><strong>Results: </strong>Overall, 522 patients with platinum-sensitive relapsed ovarian cancer were evaluated; 165 were considered unsuitable for upfront secondary cytoreduction surgery and received second-line chemotherapy. After 6 cycles of neoadjuvant chemotherapy, secondary cytoreduction surgery was considered feasible in 48 patients (29.1%, group A), while 117 patients (70.9%, group B) remained ineligible for surgery. Predictors of secondary cytoreduction surgery feasibility were analyzed. Multivariate analysis identified a favorable modeled CA125 elimination rate constant K score at second-line chemotherapy (OR 7.29, 95% CI 2.91 to 18.30, p < .001) as the only independent predictor. Patients eligible for delayed secondary cytoreduction surgery showed significantly longer progression-free survival 2 and post-relapse survival (median progression-free survival 2 12.5 vs 7.9, p < .001; median post-relapse survival: not reached vs 28.5, p = .002).</p><p><strong>Conclusions: </strong>In a real-life approach in a tertiary oncological center, we showed that around 30% of women with platinum-sensitive relapsed ovarian cancer, initially deemed unsuitable for secondary cytoreduction surgery, can potentially undergo delayed secondary cytoreduction surgery following a favorable response to 6 cycles of neoadjuvant chemotherapy.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101824"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer.","authors":"Emma Collier, Pamela Soberanis Pina, Michelle McMullen, Eduardo Gonzalez-Ochoa, Jinfeng Zou, Zhen Zhao, Lisa Avery, Valerie Bowering, Anthony Msan, Neesha Dhani, Amit M Oza, Kathy Han, Scott V Bratman, Stephanie Lheureux","doi":"10.1016/j.ijgc.2025.101755","DOIUrl":"10.1016/j.ijgc.2025.101755","url":null,"abstract":"<p><strong>Objective: </strong>Despite intense multi-modal treatment, the prognosis for advanced cervical cancer remains poor. The recent increase in cervical cancer cases worldwide highlights an urgent need for clinically validated biomarkers to guide patient management. Our pilot study investigates the utility of human papillomavirus (HPV) circulating tumor deoxy ribonucleic acid (ctDNA) in metastatic and recurrent cervical cancer. We investigated the association of HPV ctDNA levels, early kinetics, and detection of viral-host integration sites with response and outcomes.</p><p><strong>Methods: </strong>Serial plasma samples were prospectively collected from 21 patients with metastatic/recurrent cervical cancer. HPV ctDNA genotyping and quantification were conducted using a previously validated hybrid capture next-generation sequencing-based method. Mutation profiles within ctDNA were investigated simultaneously using a bespoke panel. In addition, high-confidence HPV integration was detected and quantified in ctDNA using SearcHPV. Differences in progression-free survival and overall survival were also evaluated between patients with high-confidence integration sites detected at baseline and those with low or no-confidence integration sites using the Kaplan-Meier method and log-rank tests to compare groups.</p><p><strong>Results: </strong>This pilot study cohort included 21 patients with HPV-associated cervical cancer. Treatments included front-line platinum-based chemotherapy without (n = 4) or with (n = 5) bevacizumab, bevacizumab monotherapy (n = 2), or subsequent therapy (n = 7). A total of 3 previously treated patients were included to study HPV kinetics during observation. At baseline, HPV ctDNA was detected in 20 of 21 patients (95.2%). From baseline to the first assessment, a change in HPV ctDNA was significantly associated with type of response in patients on treatment (n = 18) (p = .049) and across all patients (n = 21) (p = .008). A total of 26 unique mutations were detected in either plasma or tissue. Of these, 11 of 26 were only detected in plasma, 9 of 26 were only detected in tissue, and 6 of 26 were detected in plasma and tissue. Patients with a high-confidence HPV integration site detected within ctDNA at baseline have inferior overall survival compared with patients with low-confidence or undetectable integration.</p><p><strong>Conclusions: </strong>In this pilot study, a decrease in HPV ctDNA was associated with response to treatment in metastatic and recurrent cervical cancer. HPV site integration and mutation-based ctDNA may have application to personalized therapy and should be evaluated in larger studies.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101755"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of survival and mortality in pelvic exenteration for gynecologic malignancies: a systematic review, meta-analyses, and meta-regression study.","authors":"Violante Di Donato, Evangelos Kontopantelis, Emanuele De Angelis, Roberta Maria Arseni, Giusi Santangelo, David Cibula, Roberto Angioli, Francesco Plotti, Ludovico Muzii, Giuseppe Vizzielli, Roberto Tozzi, Vito Chiantera, Giuseppe Caruso, Andrea Giannini, Giovanni Scambia, Nadeem R Abu-Rustum, Pierluigi Benedetti Panici, Giorgio Bogani","doi":"10.1016/j.ijgc.2025.101829","DOIUrl":"10.1016/j.ijgc.2025.101829","url":null,"abstract":"<p><strong>Objective: </strong>Pelvic exenteration is a radical surgery for advanced or recurrent pelvic tumors, requiring careful patient selection and a multi-disciplinary approach. Despite advancements, it remains high-risk, with limited data on outcomes. The present meta-analysis evaluates survival, mortality, and trends to clarify its role in gynecologic oncology.</p><p><strong>Methods: </strong>A systematic search was conducted in January 2025 to identify studies on pelvic exenteration outcomes for gynecologic malignancies. Studies with at least 10 patients reporting 5-year overall survival or 30-day mortality were included. Data extracted included patient and surgical characteristics, and a scoring system based on study design, sample size, and center volume was used to include high-quality studies (score ≥3). Poisson regression models were used to analyze the associations between predictors and outcomes, with results expressed as incidence rate ratios and a 95% CI.</p><p><strong>Results: </strong>A total of 46 studies involving 4417 patients met the inclusion criteria. Most patients underwent pelvic exenteration for cervical cancer (N = 3183). Positive pelvic and aortic nodal involvement were key predictors of reduced 5-year overall survival, decreasing by 3.9% and 5.9% per 1% increase in nodal positivity, respectively. Pelvic wall involvement also significantly reduced survival by 15.9%. The 30-day mortality rate was 5.1%, with sepsis (27.2%) being the leading cause of death. Peri-operative mortality decreased significantly over time, with each year of publication associated with a 2.6% decrease in incidence rate. However, pelvic sidewall involvement and total exenteration increased 30-day mortality by 11.5% and 0.7%, respectively.</p><p><strong>Conclusions: </strong>Pelvic exenteration remains a viable but high-risk option for select patients with advanced gynecologic malignancies. Pre-operative assessment and multi-disciplinary planning are essential for optimizing outcomes.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 6","pages":"101829"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}